"On 23 February 2023, Akorn, Inc. announced it had entered Chapter VII bankruptcy and immediately ceased operations. At the time of this announcement Akorn was the market leader for prilocaine 2.5% and lidocaine 2.5% cream, holding market share exceeding 60%.
Together Acrux and Padagis are working to maximise the opportunity arising from Akorn’s bankruptcy".
Future dividends from this company will surprise the doubters.
The current share price is unbelievably cheap.
ACR Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
